慢性肾脏病所致心脏功能障碍中的血小板反应蛋白-1：仅仅是一种生物标志物吗？ - Suppr

Thrombospondin-1 in Chronic Kidney Disease Driven Cardiac Dysfunction: More Than Just a Biomarker?

作者信息

Kiss Attila

机构信息

Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Austria.

出版信息

JACC Basic Transl Sci. 2024 May 27;9(5):628-630. doi: 10.1016/j.jacbts.2024.03.008. eCollection 2024 May.

DOI:10.1016/j.jacbts.2024.03.008

PMID:38984041

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11228109/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c019/11228109/253ef159c170/ga1.jpg

相似文献

Thrombospondin-1 in Chronic Kidney Disease Driven Cardiac Dysfunction: More Than Just a Biomarker?

JACC Basic Transl Sci. 2024 May 27;9(5):628-630. doi: 10.1016/j.jacbts.2024.03.008. eCollection 2024 May.

Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.

Exp Biol Med (Maywood). 2021 Dec;246(23):2511-2521. doi: 10.1177/15353702211035058. Epub 2021 Aug 3.

Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics.

Front Cardiovasc Med. 2022 May 20;9:868658. doi: 10.3389/fcvm.2022.868658. eCollection 2022.

Thrombospondin-1 Drives Cardiac Remodeling in Chronic Kidney Disease.

JACC Basic Transl Sci. 2024 Mar 27;9(5):607-627. doi: 10.1016/j.jacbts.2024.01.010. eCollection 2024 May.

Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction.

Stem Cells Transl Med. 2022 Mar 3;11(1):59-72. doi: 10.1093/stcltm/szab004.

Correlation Between Liver Stiffness and Diastolic Function, Left Ventricular Hypertrophy, and Right Cardiac Function in Patients With Ejection Fraction Preserved Heart Failure.

Front Cardiovasc Med. 2021 Nov 25;8:748173. doi: 10.3389/fcvm.2021.748173. eCollection 2021.

Cardiovascular Alterations and Structural Changes in the Setting of Chronic Kidney Disease: a Review of Cardiorenal Syndrome Type 4.

SN Compr Clin Med. 2023;5(1):15. doi: 10.1007/s42399-022-01347-2. Epub 2022 Dec 3.

Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.

Circ Heart Fail. 2016 Nov;9(11). doi: 10.1161/CIRCHEARTFAILURE.116.003381.

Endothelial-Mesenchymal Transition in Heart Failure With a Preserved Ejection Fraction: Insights Into the Cardiorenal Syndrome.

Circ Heart Fail. 2021 Sep;14(9):e008372. doi: 10.1161/CIRCHEARTFAILURE.121.008372. Epub 2021 Aug 19.

Osteopontin Promotes Left Ventricular Diastolic Dysfunction Through a Mitochondrial Pathway.

J Am Coll Cardiol. 2019 Jun 4;73(21):2705-2718. doi: 10.1016/j.jacc.2019.02.074.

本文引用的文献

Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in understanding pathophysiology.

Clin Kidney J. 2023 Apr 18;16(11):1786-1803. doi: 10.1093/ckj/sfad085. eCollection 2023 Nov.

Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats.

JACC Basic Transl Sci. 2023 May 31;8(9):1160-1176. doi: 10.1016/j.jacbts.2023.03.003. eCollection 2023 Sep.

Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling.

Circulation. 2021 Dec 21;144(25):2021-2034. doi: 10.1161/CIRCULATIONAHA.121.055732. Epub 2021 Nov 22.

Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls.

Mech Ageing Dev. 2021 Sep;198:111540. doi: 10.1016/j.mad.2021.111540. Epub 2021 Jul 6.

Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets.

Toxins (Basel). 2021 Feb 13;13(2):142. doi: 10.3390/toxins13020142.

Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.

Mol Aspects Med. 2019 Feb;65:70-99. doi: 10.1016/j.mam.2018.07.001. Epub 2018 Aug 2.

Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Nat Rev Nephrol. 2016 Oct;12(10):610-23. doi: 10.1038/nrneph.2016.113. Epub 2016 Aug 30.

Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability.

Dis Markers. 2015;2015:586569. doi: 10.1155/2015/586569. Epub 2015 Apr 5.

Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease.

Am J Kidney Dis. 2001 Mar;37(3):601-11. doi: 10.1053/ajkd.2001.22087.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Thrombospondin-1 in Chronic Kidney Disease Driven Cardiac Dysfunction: More Than Just a Biomarker?

作者信息

Kiss Attila

机构信息

Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, Vienna, Austria.

出版信息

JACC Basic Transl Sci. 2024 May 27;9(5):628-630. doi: 10.1016/j.jacbts.2024.03.008. eCollection 2024 May.

DOI:10.1016/j.jacbts.2024.03.008

PMID:38984041

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11228109/

Abstract

摘要

相似文献

Thrombospondin-1 in Chronic Kidney Disease Driven Cardiac Dysfunction: More Than Just a Biomarker?

JACC Basic Transl Sci. 2024 May 27;9(5):628-630. doi: 10.1016/j.jacbts.2024.03.008. eCollection 2024 May.

Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction.

Exp Biol Med (Maywood). 2021 Dec;246(23):2511-2521. doi: 10.1177/15353702211035058. Epub 2021 Aug 3.

Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics.

Front Cardiovasc Med. 2022 May 20;9:868658. doi: 10.3389/fcvm.2022.868658. eCollection 2022.

Thrombospondin-1 Drives Cardiac Remodeling in Chronic Kidney Disease.

JACC Basic Transl Sci. 2024 Mar 27;9(5):607-627. doi: 10.1016/j.jacbts.2024.01.010. eCollection 2024 May.

Allogeneic Cell Combination Therapy Ameliorates Chronic Kidney Disease-Induced Heart Failure with Preserved Ejection Fraction.

Stem Cells Transl Med. 2022 Mar 3;11(1):59-72. doi: 10.1093/stcltm/szab004.

Correlation Between Liver Stiffness and Diastolic Function, Left Ventricular Hypertrophy, and Right Cardiac Function in Patients With Ejection Fraction Preserved Heart Failure.

Front Cardiovasc Med. 2021 Nov 25;8:748173. doi: 10.3389/fcvm.2021.748173. eCollection 2021.

Cardiovascular Alterations and Structural Changes in the Setting of Chronic Kidney Disease: a Review of Cardiorenal Syndrome Type 4.

SN Compr Clin Med. 2023;5(1):15. doi: 10.1007/s42399-022-01347-2. Epub 2022 Dec 3.

Dual Endothelin-A/Endothelin-B Receptor Blockade and Cardiac Remodeling in Heart Failure With Preserved Ejection Fraction.

Circ Heart Fail. 2016 Nov;9(11). doi: 10.1161/CIRCHEARTFAILURE.116.003381.

Endothelial-Mesenchymal Transition in Heart Failure With a Preserved Ejection Fraction: Insights Into the Cardiorenal Syndrome.

Circ Heart Fail. 2021 Sep;14(9):e008372. doi: 10.1161/CIRCHEARTFAILURE.121.008372. Epub 2021 Aug 19.

Osteopontin Promotes Left Ventricular Diastolic Dysfunction Through a Mitochondrial Pathway.

J Am Coll Cardiol. 2019 Jun 4;73(21):2705-2718. doi: 10.1016/j.jacc.2019.02.074.

本文引用的文献

Cardiomyopathy in chronic kidney disease: clinical features, biomarkers and the contribution of murine models in understanding pathophysiology.

Clin Kidney J. 2023 Apr 18;16(11):1786-1803. doi: 10.1093/ckj/sfad085. eCollection 2023 Nov.

Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats.

JACC Basic Transl Sci. 2023 May 31;8(9):1160-1176. doi: 10.1016/j.jacbts.2023.03.003. eCollection 2023 Sep.

Extracellular Matrix in Heart Failure: Role of ADAMTS5 in Proteoglycan Remodeling.

Circulation. 2021 Dec 21;144(25):2021-2034. doi: 10.1161/CIRCULATIONAHA.121.055732. Epub 2021 Nov 22.

Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls.

Mech Ageing Dev. 2021 Sep;198:111540. doi: 10.1016/j.mad.2021.111540. Epub 2021 Jul 6.

Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets.

Toxins (Basel). 2021 Feb 13;13(2):142. doi: 10.3390/toxins13020142.

Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.

Mol Aspects Med. 2019 Feb;65:70-99. doi: 10.1016/j.mam.2018.07.001. Epub 2018 Aug 2.

Heart failure and kidney dysfunction: epidemiology, mechanisms and management.

Nat Rev Nephrol. 2016 Oct;12(10):610-23. doi: 10.1038/nrneph.2016.113. Epub 2016 Aug 30.

Cardiovascular biomarkers in chronic kidney disease: state of current research and clinical applicability.

Dis Markers. 2015;2015:586569. doi: 10.1155/2015/586569. Epub 2015 Apr 5.

Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease.

Am J Kidney Dis. 2001 Mar;37(3):601-11. doi: 10.1053/ajkd.2001.22087.

Thrombospondin-1 in Chronic Kidney Disease Driven Cardiac Dysfunction: More Than Just a Biomarker?

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Thrombospondin-1 in Chronic Kidney Disease Driven Cardiac Dysfunction: More Than Just a Biomarker?

作者信息

机构信息

出版信息

相似文献

本文引用的文献